Alpha 2.0
Login Register
» Authors » Aatke van der Maas

Aatke van der Maas

Explore the profile of Aatke van der Maas including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 378
Followers 0
Related Specialties
Rheumatology
General Medicine
Pharmacology
Top 10 Co-Authors
Alfons A den Broeder
Noortje van Herwaarden
Nathan den Broeder
Frank H J van den Hoogen
Bart J F van den Bemt
Ronald F van Vollenhoven
Chantal A M Bouman
Thomas E Bolhuis
Frank Hj van den Hoogen
Wietske Kievit
Published In
Ann Rheum Dis
Rheumatology (Oxford)
J Rheumatol
RMD Open
Clin Exp Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review
Bolhuis T, Bosch P, Falzon L, Owen C, Yates M, Mackie S, et al.
Rheumatology (Oxford) . 2024 Aug; 64(2):455-469. PMID: 39133187
Objective: To perform a systematic literature review on definitions and instruments used to measure remission, relapse and disease activity in polymyalgia rheumatica (PMR), to inform an OMERACT project to endorse...
2.
Effect of using the Simple Erosion Narrowing Score or Sharp/van der Heijde score on the power of rheumatoid arthritis clinical trials to detect differences in radiographic progression
den Broeder N, Bolhuis T, van Herwaarden N, Bergstra S, Bouman C, van den Hoogen F, et al.
Rheumatology (Oxford) . 2024 Jun; 64(3):1464-1468. PMID: 38867707
Objectives: The Simple Erosion Narrowing Score (SENS) is a simplification of the Sharp/van der Heijde score (SHS). Previous studies found SENS and SHS to have very similar measurement properties, but...
3.
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial
den Broeder N, Verhoef L, de Man Y, Kok M, Thurlings R, van der Weele W, et al.
RMD Open . 2024 Apr; 10(2). PMID: 38599654
Background: The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per...
4.
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study
van der Togt C, den Broeder N, Boonstra M, van der Maas A, den Broeder A, van Herwaarden N
Rheumatology (Oxford) . 2024 Feb; 64(2):533-540. PMID: 38346712
Objective: The objective of this study was to investigate the safety and effectiveness of disease activity-guided dose optimization of TNF inhibitors in RA over 10 years. Methods: The study involved...
5.
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial
Bolhuis T, Marsman D, den Broeder A, den Broeder N, van der Maas A
Lancet Rheumatol . 2024 Jan; 5(4):e208-e214. PMID: 38251523
Background: Rituximab was effective for patients with polymyalgia rheumatica in the 21-week BRIDGE-PMR randomised controlled trial. Here, we aimed to assess rates of glucocorticoid-free remission up to 1 year after...
6.
Non-Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study
den Broeder N, den Broeder A, Verhoef L, van den Hoogen F, van der Maas A, van den Bemt B
Clin Pharmacol Ther . 2023 Jul; 114(4):810-814. PMID: 37429827
Tocilizumab and sarilumab are IL-6-receptor antagonists registered for rheumatoid arthritis (RA), with equal effectiveness and safety. Switching from tocilizumab to sarilumab could be a strategy to reduce injection burden, in...
7.
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov A, Mackie S, Hauge E, Toro-Gutierrez C, Hansen I, Hemmig A, et al.
Rheumatology (Oxford) . 2023 Jan; 62(8):2797-2805. PMID: 36637182
Objectives: To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods: An English language questionnaire was constructed by a working...
8.
The value of incorporating patient-consulted medication reconciliation in influencing drug-related actions in the outpatient rheumatology setting
van der Nat D, Huiskes V, van der Maas A, Derijks-Engwegen J, van Onzenoort H, van den Bemt B
BMC Health Serv Res . 2022 Aug; 22(1):995. PMID: 35927690
Background: Unintentional changes to patients' medicine regimens and drug non-adherence are discovered by medication reconciliation. High numbers of outpatient visits and medication reconciliation being time-consuming, make it challenging to perform...
9.
(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
Bolhuis T, Marsman D, van den Hoogen F, den Broeder A, den Broeder N, van der Maas A
BMC Rheumatol . 2022 Aug; 6(1):45. PMID: 35915465
Background: To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment. Methods: A retrospective PMR cohort (clinical diagnosis) from a...
10.
PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial
Marsman D, Bolhuis T, den Broeder N, den Broeder A, van der Maas A
Trials . 2022 Apr; 23(1):318. PMID: 35428320
Background: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC)...